Science Raises $400M Series D as PRIMA Sight-Restoring Implant Eyes US Launch


Science Corporation, the brain-computer interface (BCI) startup working to restore sight, has raised a $400 million Series D. It comes eight months after a $230 million Series C at a $1.5 billion valuation. Total capital raised since its 2021 founding now tops $900 million.

Science Raises $400M Series D as PRIMA Sight-Restoring Implant Eyes US Launch

Europe first, then the US

Khosla Ventures, the Ackman Oxman Institute, US hospital operator Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among others, took part. Science did not name a lead investor or disclose a valuation. Some press reports put it at $3.5 billion, a figure the company has not confirmed.

Science will use the money to get its PRIMA retinal implant to more patients across Europe and to prepare for a US launch. It will also expand research, manufacturing and operations, and invest substantially more in a “biohybrid” program that connects to the brain through living neurons.

A chip that does the work of dead retinal cells

PRIMA is aimed at people with geographic atrophy, the late stage of dry age-related macular degeneration. The retinal cells that handle the center of the visual field die off, and with them the central vision needed to read or recognize a face.

PRIMA lets a chip take over that job. A 2-millimeter chip is implanted under the retina, and its 378 pixels turn light into electricity. Patients wear glasses with a camera and a small projector. The camera captures a scene and the glasses beam it onto the chip as light. The chip converts it into electrical signals that stimulate the remaining retinal cells, and the brain reads those signals as shapes such as letters.

Clinical results back it up. At 12 months, 80% of patients had a clinically meaningful improvement in visual acuity, and 84% read letters, numbers and words at home. On the eye chart, that is about 25 more letters on average, roughly five lines. The results appeared in the New England Journal of Medicine this year, and 36-month data released in October showed the effect lasts. The same month Science shared its first patient with Stargardt disease, an inherited retinal condition. The technology was not built from scratch: Science bought the assets from French medical device company Pixium Vision in 2024 and carried the program forward.

Commercialization has moved fast. PRIMA received a CE mark in the European Union in July, which Science calls a first for a BCI that restores form vision, meaning the ability to read letters, numbers and words. It is available in Germany first. In the US, the FDA granted two Humanitarian Use Device designations that month, covering people blinded in both eyes by advanced geographic atrophy and people with Stargardt disease. A designation is not approval, so Science is going after a Humanitarian Device Exemption. It has not disclosed pricing, patient counts or revenue.

The founder who left Neuralink

Max Hodak, Science’s CEO, co-founded Neuralink with Elon Musk in 2016 and served as its president. He left in 2021 and founded Science that year. In September, Darius Shahida, who has been with the company from the start, became president.

Biohybrid is the next bet after PRIMA. Instead of pushing metal electrodes into the brain, it places neurons grown from stem cells on the brain’s surface and connects them biologically to existing circuits. The hope is less damage than electrodes cause. The company is reportedly designing a first human trial with Yale neurosurgery professor Murat Günel.

Competition: paralysis or sight

Most of the big names in BCI focus on helping paralyzed people control devices with thought. Neuralink raised a $650 million Series E in 2025 at a $9 billion valuation and is also developing a visual aid called Blindsight, which overlaps Science most directly. Neuralink sends signals straight to the brain’s visual area, while PRIMA uses the retina that remains in the eye. Synchron, which inserts electrodes through blood vessels, raised a $200 million Series D last November. Precision Neuroscience, which uses thin-film electrodes, raised $250 million in September. Merge Labs, co-founded by Sam Altman, closed a $250 million seed round for a noninvasive ultrasound approach.

In vision restoration, Science is the one that has cleared regulators first. Clinical figures and the valuation come from company statements and press reports and have not been independently verified.

Share

Leave a Reply

Your email address will not be published. Required fields are marked *